(CercleFinance.com) – Pfizer announced on Monday positive phase 3 results concerning its European study conducted on its pediatric pneumococcal vaccine project supposed to protect against 20 serotypes of the bacterium.
In short, the trial showed that this so-called ’20-valent’ conjugate vaccine, called 20vPnC, was able to protect vaccinated infants in a vaccination schedule consisting of three doses.
This vaccine is aimed at the active immunization of babies under one year of age in order to prevent pneumonia, but also sepsis and meningitis caused by streptococcus pneumoniae.
Pfizer says it plans to transmit this data to the European Medicines Agency (EMA), the authority in charge of examining marketing applications before their examination by the European Commission, by the end of the year. .
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
